Results of a phase II trial with cystemustine at 90 mg/m2 as a first- or second-line treatment in advanced malignant melanoma: A trial of the EORTC clinical studies group

Melanoma Research

Volumn 9, Issue 6, 1999, Pages 607-610

  Cure, H ^a   Souteyrand, P ^a   Ouabdesselam, R ^a   Roche, H ^b   Ravaud, A ^c   D'Incan, M ^a   Viens, P ^d   Fargeot, P ^e   Lentz, M A ^f   Fumoleau, P ^g   Hanauske, A ^h   Chollet, P ^a  

^a CENTRE JEAN PERRIN   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c INSTITUT BERGONIÉ   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f EORTC DATA CENTER   (Belgium)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h EORTC NDDO   (Netherlands)

Author keywords

Cystemustine; Melanoma; New nitrosourea; Phase II trial

Indexed keywords

CYSTEMUSTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APLASIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0033406682     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199912000-00011     Document Type: Article

References (13)

1. Avril MF, Bonneterre J, Cupissol D, Grob JJ, Kalis B, Fumoleau P, Kerbrat P, Israel L, Fargeot P, Lambert D, Delaunay M, Dreno B, Vilmer C, Bizzari JP, Cour V. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992; 28A(11): 1807-1811.
2. Karakousis CP, Moore R, Holyoke ED. Surgery in recurrent malignant melanoma. Cancer 1983; 52: 1342-1345.
3. Laurent R, Zultak M. Les mélanomes malins cutanés. Encycl Méd Chir Dermatol 1988; 12: 760, A10-17.
4. Mastrangelo MJ, Baker AR, Katz HR. Cutaneous melanoma. In: De Vita VT Jr, Hellmann S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1985: 1371-1422.
5. Cohen GL, Falkson CI. Current treatment options for malignant melanoma. Drugs 1998; 55(6): 791-799.
6. Balch MH, Houghton AN, Peters LJ. Cutaneous melanoma In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1993: 1612-1661.
7. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicentric phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-1878.
8. Mohr P, Weichenthal M, Abenhoff J, Stephan U, Breibart EW. Responses and long term survival after systemic chemotherapy with fotemustine in patients with advanced malignant melanoma. J Cancer Res Clin Oncol 1994: 120(suppl): R153.
9. Bizzari JP. La fotémustine dans l'indication 'mélanome malin métastatique'; analyse globale des résultats. Pathol Biol 1990; 38(8): 11-15.
10. Urosevic V, Chollet P, Adenis A, Chauvergne J, Fargeot P, Roche H, Kerbrat P, Lentz MA, Fumoleau P, Chevallier B. Results of a phase II trial with cystemustine at 60 mg/sq.m. in advanced malignant melanoma - a trial of the EORTC Clinical Screening Group. Eur J Cancer 1996; 32A(1): 181-182.
11. Garcia ED, Santolaya R, Requena T. Treatment of malignant melanoma. Ann Pharmacother 1999; 33(6): 730-738.
12. Coeffic D. Chimiothérapie et chimio-immunothérapie du mélanome malin métastatique; revue de la littérature et données récentes. Oncologie 1999; 8(1).
13. Nathan FE, Mastrangelo MJ. Systemic therapy in melanoma. Semin Surg Oncol 1998; 14(4): 319-327.